Dalteparin versus Warfarin for the Prevention of Recurrent Venous Thromboembolic Events in Cancer Patients: A Pharmacoeconomic Analysis

Author： Dranitsaris George

Publisher： Adis International

ISSN： 1170-7690

Source： PharmacoEconomics, Vol.24, Iss.6, 2006-01, pp. : 593-607

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Pharmacoeconomic Analysis of Fondaparinux Versus Enoxaparin for the Prevention of Thromboembolic Events in Orthopedic Surgery Patients

By George Dranitsaris

American Journal of Cardiovascular Drugs, Vol. 4, Iss. 5, 2004-01 ,pp. : 325-333

Adis International

Access to resources Recommend Favorite

Extended Dalteparin Prophylaxis for Venous Thromboembolic Events: Cost-Utility Analysis in Patients Undergoing Major Orthopedic Surgery

By Dranitsaris George

American Journal of Cardiovascular Drugs, Vol. 9, Iss. 1, 2009-01 ,pp. : 45-58

Adis International

Access to resources Recommend Favorite

Dalteparin alternative in VTE prevention for patients with cancer

Inpharma, Vol. 1, Iss. 1545, 2006-01 ,pp. : 5-5

Adis International

Access to resources Recommend Favorite

Dalteparin alternative in VTE prevention for patients with cancer

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 506, 2006-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Dermatan Sulfate versus Unfractionated Heparin for the Prevention of Venous Thromboembolism in Patients Undergoing Surgery for Cancer: A Cost-Effectiveness Analysis

By Attanasio E.

PharmacoEconomics, Vol. 19, Iss. 1, 2001-01 ,pp. : 57-68

Adis International

Access to resources Recommend Favorite